EUVIMEDEUVIMED entdecken
Open Access · CC0

Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody

Tin Phan, Carolin Zitzmann, Kara W Chew, Davey M Smith, Eric S Daar, David A Wohl, Joseph J Eron, Judith S Currier, Michael D Hughes, Manish C Choudhary, Rinki Deo, Jonathan Z Li und 4 weitere

PLOS Pathogens · 2024

DOI: 10.1371/journal.ppat.1011680 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Tin Phan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Theoretical Biology & Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Monoclonal, Spike Glycoprotein, Coronavirus, COVID-19. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To mitigate the loss of lives during the COVID-19 pandemic, emergency use authorization was given to several anti-SARS-CoV-2 monoclonal antibody (mAb) therapies for the treatment of mild-to-moderate COVID-19 in patients with a high risk of progressing to severe disease. Monoclonal antibodies used to treat SARS-CoV-2 target the spike protein of the virus and block its ability to enter and infect target cells. Monoclonal antibody therapy can thus accelerate the decline in viral load and lower hospitalization rates among high-risk patients with variants susceptible to mAb therapy. However, viral resistance has been observed, in some cases leading to a transient viral rebound that can be as large as 3–4 orders of magnitude. As mAbs represent a proven treatment choice for SARS-CoV-2 and other viral infections, evaluation of treatment-emergent mAb resistance can help uncover underlying pathobiology of SARS-CoV-2 infection and may also help in the development of the next generation of mAb therapies. Although resistance can be expected, the large rebounds observed are much more difficult to explain. We hypothesize replenishment of target cells is necessary to generate the high transient viral rebound. Thus, we formulated two models with different mechanisms for target cell replenishment (homeostatic proliferation and return from an innate immune response antiviral state) and fit them to data from persons with SARS-CoV-2 treated with a mAb. We showed that both models can explain the emergence of resistant virus associated with high transient viral rebounds. We found that variations in the target cell supply rate and adaptive immunity parameters have a strong impact on the magnitude or observability of the viral rebound associated with the emergence of resistant virus. Both variations in target cell supply rate and adaptive immunity parameters may explain why only some individuals develop observable transient resistant viral rebound. Our study highlights the conditions that can lead to resistance and subsequent viral rebound in mAb treatments during acute infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antibodies, MonoclonalSpike Glycoprotein, CoronavirusCOVID-19COVID-19 Drug TreatmentHumansAntibodies, ViralDrug Resistance, ViralViral LoadAntiviral AgentsAntibodies, Neutralizing

Substanzen

Antibodies, MonoclonalSpike Glycoprotein, CoronavirusAntibodies, Viralspike protein, SARS-CoV-2Antiviral AgentsAntibodies, Neutralizing

Autor:innen und Institutionen

  • Theoretical Biology & Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
  • Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.
  • Department of Medicine, University of California, San Diego, California, United States of America.
  • Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, United States of America.
  • Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States of America.
  • Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

ORCID-Profile: Alan S Perelson

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS
  • National Institutes of Health
  • Los Alamos National Laboratory

Zitieren

APA

Phan, T., Zitzmann, C., Chew, K. W., Smith, D. M., Daar, E. S., Wohl, D. A., Eron, J. J., Currier, J. S., Hughes, M. D., Choudhary, M. C., Deo, R., Li, J. Z., Ribeiro, R. M., Ke, R., Perelson, A. S., & ACTIV-2/A5401 Study Team (2024). Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011680

Vancouver

Phan T, Zitzmann C, Chew KW, Smith DM, Daar ES, Wohl DA, et al. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1011680

BibTeX
@article{Phan2024,
  author = {Phan, Tin and Zitzmann, Carolin and Chew, Kara W and Smith, Davey M and Daar, Eric S and Wohl, David A and Eron, Joseph J and Currier, Judith S and Hughes, Michael D and Choudhary, Manish C and Deo, Rinki and Li, Jonathan Z and Ribeiro, Ruy M and Ke, Ruian and Perelson, Alan S and ACTIV-2/A5401 Study Team, ACTIV-2/A5401 Study Team},
  title = {Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody},
  journal = {PLOS Pathogens},
  year = {2024},
  doi = {10.1371/journal.ppat.1011680}
}
Kostenlos starten →